Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Inpixon Launches New Enterprise Apps Section on its Website to Reflect Inpixon's Broad Solution Set for Large Organizations
PALO ALTO, Calif., April 18, 2022 /PRNewswire/ -- Inpixon® (NASDAQ:INPX), the
Gainers
908 Devices (NASDAQ:MASS) stock increased by 11.2% to $17.29 during Monday's after-market session. The market value of their outstanding shares is at $536.8 million. As per the news, the Q4 earnings report came out today.